May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
The uPA/uPAR System in Choroidal Neovascularization: A Target for Anti-Angiogenic Therapy
A. Das; P.G. McGuire; T.R. Jones; N. Talarico; E. Warren
Author Affiliations & Notes
  • A. Das
    Dept Surgery/Div Ophthalmology, Univ of New Mexico Hlth Sci, Albuquerque, NM, United States
  • P.G. McGuire
    Dept Cell Biology and Physiol, Univ of New Mexico Hlth Sci, Albuquerque, NM, United States
  • T.R. Jones
    Angstrom Pharmaceuticals, San Diego, CA, United States
  • N. Talarico
    Angstrom Pharmaceuticals, San Diego, CA, United States
  • E. Warren
    Angstrom Pharmaceuticals, San Diego, CA, United States
  • Footnotes
    Commercial Relationships  A. Das, Angstrom Pharmaceuticals R; P.G. McGuire, Angstrom Pharmaceuticals R; T.R. Jones, Angstrom Pharmaceuticals E; N. Talarico, None; E. Warren, None.
  • Footnotes
    Support  NIH Grant EY12604
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 3941. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      The uPA/uPAR System in Choroidal Neovascularization: A Target for Anti-Angiogenic Therapy
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      A. Das, P.G. McGuire, T.R. Jones, N. Talarico, E. Warren; The uPA/uPAR System in Choroidal Neovascularization: A Target for Anti-Angiogenic Therapy . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3941.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: We have previoulsy shown a role for urokinase (uPA) and its receptor uPAR during retinal neovasculariztaion in an animal model. The purpose of this study was to examine whether inhibition of this proteolytic system can suppress the extent of choroidal neovascularization (CNV). Methods: CNV was induced in C57/Bl6 mice by laser photocoagulation (Argon green, 100 micron spot size, 0.1 sec duration and 120mW intensity) using the slit lamp delivery system. Production of a vaporization bubble indicating rupture of Bruch's membrane, was used as an endpoint during laser treatment. Over the next two weeks following laser treatment, animals were treated with an IP injection of an inhibitor of uPA /uPAR interaction (A6 peptide, 100mg/kg). Control, laser treated, animals received IP injections of PBS for the same period of time. Following treatment, eyes were removed and examined by staining frozen sections with GSA lectin. The extent of neovascularization in the burn areas was quantitated using the MetaMorph image analysis software. Results: Histological analysis of mice treated with A6 showed significant inhibition of CNV (up to 70%, p<0.05) with no detectable toxic side effects. Conclusions: Significant inhibition of CNV was seen when cell-surface associated uPA/uPAR activity was prevented with the peptide A6. These data suggest a potential new anti-angiogenic therapy for CNV as seen in age-related macular degeneration.

Keywords: choroid: neovascularization • age-related macular degeneration • proteolysis 
© 2003, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept